HER2 leads the clearest 2025 patent landscape with 302 ADC families; narrower modality slices crown PD-L1, MASP-2 and GD2

Asked:
“what molecular targets got most patents in different therapeutic modalities and jurisdictions last year ?”

No public dataset ranks every molecular target by modality separately for USPTO, EPO, CNIPA, JPO and other offices for patents filed or granted only in 2025. The defensible evidence is five modality-specific, mostly cumulative patent landscapes whose searches extend into 2025 — a best-evidence shortlist drawn from four independent sources, not a jurisdiction-by-jurisdiction league table. Counts below mix patent families and patent records and must not be compared across rows.

Blue = leading target in that landscape  ·  pale blue = runner-up  ·  bars are scaled within each modality card only, because units and scopes differ across landscapes. All figures are cumulative landscapes through 2025, not patents newly filed in 2025.

HER2 is the one high-volume leader in a broad, well-defined landscape with an explicit 2025-06-30 cutoff: 302 ADC patent families, 63% ahead of runner-up CD79b (185). frontiersin.org
In nanobodies, checkpoint targets dominate: PD-L1 (177 families) outpaces PD-1 (109) across Derwent coverage of 60 issuing authorities. europepmc.org
The only finding with explicit multi-jurisdiction breadth is small: at least 12 anti-MASP-2 antibody records spanning WO, AU, US, CA, CN, SG, JP, MX, ES and OA. patsnap.com
GD2 leads two separate neuroblastoma modality slices through August 2025 — antibodies (10 families, ahead of GPC2) and cellular immunotherapy (4 families versus PHOX2B’s 2). sites.google.com

How to read these numbers

All source rows

ModalityLeading targetCountMetricScopeCutoffRunner-upSource
Antibody-drug conjugate (ADC)HER2302Patent familiesGlobal2025-06-30CD79b (n = 185)frontiersin.org
antibody-drug conjugate (ADC)HER2302patent familiesglobal2025-06-30CD79b (n = 185)doi.org
Nanobody (Nb)PD-L1177Patent familiesGlobal2025PD-1 (109 patent families)europepmc.org
Complement pathway inhibition (MASP-2 inhibitory antibodies)MASP-212patent records9+ jurisdictions (WO, AU, US, CA, CN, SG, JP, MX, ES, OA)2025—patsnap.com
AntibodiesGD210patent familiesGlobal2025GPC2sites.google.com
Cellular immunotherapyGD24patent familiesGlobal2025PHOX2B (two patents)sites.google.com

Method: 6 source rows gathered in 2025 from 4 independent hosts; two duplicate ADC references to the same Frontiers study (article and DOI) are consolidated into one finding, giving 5 findings. Each count is the number of patent families (or, for MASP-2, patent records) attributed to a target in that modality’s cumulative patent landscape through its stated 2025 cutoff. Counts use different units, scopes and search methods and are not comparable across rows; no office-by-office ranking was cut — none exists in the public data found.

This report was generated automatically by Keenable SELECT at a user's request, from publicly available web sources linked herein. Keenable does not review, verify, or endorse its contents and makes no representation as to accuracy, completeness, or timeliness; AI-based extraction may contain errors. Nothing in this report is investment, legal, financial, or other professional advice. All trademarks and referenced content remain the property of their respective owners; no affiliation or endorsement is implied. To report an error, rights concern, or request removal: legal@keenable.ai.

Keenable SELECTAsk your own question
Made with Keenable SELECT